Lenni Fugazy
Surgical · Chicago, ILNPI 1619922481
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.
Across 129 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$441
- Pfizer$337
- Novartis$243
- Lilly USA, LLC$209
- Novo Nordisk$166
- GSK$129
- plus $557 from 14 others
What the payments were for
- Food & beverage$2,082100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 34 | $441 |
| Pfizer | 21 | $337 |
| Novartis | 13 | $243 |
| Lilly USA, LLC | 12 | $209 |
| Novo Nordisk | 10 | $166 |
| GSK | 8 | $129 |
| Merck | 4 | $81 |
| AstraZeneca | 4 | $58 |
| Abbott | 3 | $55 |
| Dexcom, Inc. | 3 | $54 |
| Boehringer Ingelheim | 3 | $52 |
| Exact Sciences | 3 | $47 |
| Vivus LLC | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $35 |
| Almatica Pharma LLC | 2 | $34 |
| Astellas Pharma US Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
How this compares
$2,082 in reported general payments places this provider in the 85th percentile of 335 surgical providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 58 | $442 |
| Doxycycline Hyclate | 34 | $270 |
| Lisinopril | 33 | $245 |
| Amlodipine Besylate | 20 | $243 |
| Rosuvastatin Calcium | 21 | $218 |
| Levothyroxine Sodium | 19 | $208 |
| Torsemide | 13 | $196 |
| Gabapentin | 11 | $182 |
| Atorvastatin Calcium | 28 | $180 |
| Omeprazole | 12 | $179 |
| Pravastatin Sodium | 11 | $153 |
| Zolpidem Tartrate | 16 | $145 |
| Sertraline Hcl | 11 | $136 |
| Trazodone Hcl | 15 | $128 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $34 | $13611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 335 surgical providers in Illinois.
Other surgical in Chicago
- Rachel KomornikChicago$19K
- Laura RyanChicago$17K
- Jocelin SistoChicago$6K
- Kelly HoyertChicago$6K
- Stephanie GurneyChicago$5K
- Monica FiehlerChicago$4K
- McKenzie GreeneChicago$4K
- Laura OsobaChicago$3K
- Christopher McGeeChicago$3K
- Keith LadendorfChicago$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.